Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 21, Issue 11, Pages 1423-1430Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514564484
Keywords
Aggressive multiple sclerosis; autologous hematopoietic stem cell transplantation; conditioning regimen; lympho-ablation; multiple sclerosis; relapsing-remitting multiple sclerosis; transplantation; treatment methods
Categories
Funding
- Teva
- Merck Serono
- Bayer
- Novartis
- Roche
- Allergan
- Biogen Idec
- Sanofi-Genzyme
- Bayer Schering
- Genzyme
- Sanofi-Aventis
- Teva Pharmaceuticals
Ask authors/readers for more resources
Background: Autologous hematopoietic stem cell transplantation (AHSCT) has been successfully used to treat aggressive forms of multiple sclerosis (MS) that are unresponsive to approved therapies. In the last years, in view of the risk of mortality related to the procedure, the utilization of low-intensity conditioning regimens has been considered. Objective: To report magnetic resonance imaging (MRI) and clinical data in a small cohort of patients treated with a low-intensity lympho-ablative regimen, followed by AHSCT. Methods: Seven patients affected by relapsing-remitting MS (RRMS) underwent AHSCT, with cyclophosphamide 120 mg/kg in 2 days as the conditioning regimen; and were then followed with serial MRI evaluations until 36 months, with clinical evaluations until 60 months. Results: The mean number of gadolinium (Gd)-enhancing lesions significantly decreased after treatment, but a complete suppression of inflammatory activity was not obtained. No deaths occurred, but every patient developed adverse events, although not severe. After 5 years of follow-up, two patients remained stable, one patient markedly improved and four patients had a mild progression of the disease. Only one patient experienced a relapse after treatment. Conclusion: A low-intensity conditioning regimen with AHSCT has a profound effect on MRI inflammation and relapses, but is not able to completely abrogate MRI activity and disease progression of aggressive RRMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available